Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10–15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown. Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.

Complementemia in pregnancies with antiphospholipid syndrome / Tabacco, S.; Giannini, A.; Garufi, C.; Botta, A.; Salvi, S.; Del Sordo, G.; Benedetti Panici, P.; Lanzone, A.; De Carolis, S.. - In: LUPUS. - ISSN 0961-2033. - 28:13(2019), pp. 1503-1509. [10.1177/0961203319882507]

Complementemia in pregnancies with antiphospholipid syndrome

Tabacco S.;Giannini A.
;
Garufi C.;Salvi S.;Benedetti Panici P.;
2019

Abstract

Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10–15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown. Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.
anticardiolipin antibodies; antiphospholipid syndrome; complement; complement activation; lupus anticoagulant; pregnancy
01 Pubblicazione su rivista::01m Editorial/Introduzione in rivista
Complementemia in pregnancies with antiphospholipid syndrome / Tabacco, S.; Giannini, A.; Garufi, C.; Botta, A.; Salvi, S.; Del Sordo, G.; Benedetti Panici, P.; Lanzone, A.; De Carolis, S.. - In: LUPUS. - ISSN 0961-2033. - 28:13(2019), pp. 1503-1509. [10.1177/0961203319882507]
File allegati a questo prodotto
File Dimensione Formato  
Tabacco_Complementemia-in pregnancies-with_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 198.3 kB
Formato Adobe PDF
198.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Tabacco_Complementemia-in pregnancies-with_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 198.64 kB
Formato Adobe PDF
198.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1652047
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact